DePuy Synthes and Ethicon to present knee and hip procedural solutions at EFORT

1 June 2017 (Last Updated June 1st, 2017 18:30)

DePuy Synthes and Ethicon, divisions of Johnson and Johnson (J&J) Medical Devices unit, have partnered to present their knee and hip procedural solutions at the 18th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress, in Vienna from 31 May to 2 June.

DePuy Synthes and Ethicon, divisions of Johnson and Johnson (J&J) Medical Devices unit, have partnered to present their knee and hip procedural solutions at the 18th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress, in Vienna from 31 May to 2 June.

The intraoperative solutions aim to decrease the rate of surgical site infections (SSIs) for minimising costs, as well as increasing patient outcomes and satisfaction.

SSIs are reported to impact orthopaedic patients, reducing their quality of life and hindering knee and hip arthroplasty procedures.

DePuy Synthes will showcase its Attune Knee System to improve patient functional outcomes, surgeon performance, provider efficacy, and the Corail Pinnacle Total Hip System for total hip replacement.

"Our range of complementary technologies seek to address the need for standardisation and efficiencies in the operating room while mitigating the threat of surgical site infections."

The knee system is devised to provide stability and motion of knee replacement, while the construct design of the hip system is expected to minimise revision risk and costs.

J&J Medical Devices EMEA company group chair Michelle Brennan said: “Our range of complementary technologies seek to address the need for standardisation and efficiencies in the operating room while mitigating the threat of surgical site infections, which can be an unexpected and traumatic event during a patient’s journey to recovery”.

Ethicon will display its wound closure offerings such as Dermabond Prineo Skin Closure System, and products from its Plus Sutures line, including the Stratafix Plus Knotless Tissue Control Device.

The skin closure system is developed to provide a microbial barrier with 99% protection from organisms in-vitro for 72 hours, while the sutures come with antibacterial triclosan coating and prevent in-vitro colonisation of the suture by bacteria known to cause SSIs.